SynteractHCR Continues to Show International Clinical Trial Expertise by Participating in European Conferences This Spring
SynteractHCR , a full-service, international contract research organization (CRO), will present and exhibit at several European biopharma events this spring. The events include Clinical Trials in Central and Eastern Europe on April 11 – 12, ePharma Day 2017 on May 3 and Outsourcing in Clinical Trials (OCT) Europe on May 16 – 17.
Dr. Martine Dehlinger-Kremer , global vice president of medical and regulatory affairs, will present at Session 2, “Update on Regulation, Compliance, Legal & Ethical Legislative Developments” on Tuesday, April 25, at 9:55 a.m. at Clinical Trials in Central and Eastern Europe in Budapest, Hungary. With more than 26 years of regulatory affairs leadership experience, Dr. Dehlinger-Kremer will provide invaluable insight on the latest clinical trial regulatory initiatives. Attendees will leave the presentation with a better understanding on how a regulatory agency can support earlier access to medical products.
At ePharma Day 2017 in Frankfurt, Germany, Dr. Dehlinger-Kremer, with others serving on the scientific board, will provide opening remarks and welcome conference attendees on Wednesday, May 3, at 9:30 a.m. That same day, SynteractHCR Director Regulatory Affairs, Dr. Ludwig Baumann, will present “EU Portal and Database – User Acceptance Testing and Status of Implementation” at 12:10 p.m.
SynteractHCR will make its final spring European conference stop in Barcelona for OCT Europe , and will exhibit at booth #7. OCT Europe brings together executives working within clinical operations and outsourcing across Europe, providing the opportunity for attendees to discuss current challenges in the industry.
Attendees interested in meeting with the SynteractHCR team at these events may contact Chief Commercial Officer Matt Smith at 760-268-8200 or firstname.lastname@example.org .
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision ” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
Nikki Sachman, 760-230-2424
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PMI21.3.2018 13:34 | pressemeddelelse
Philip Morris International Shifts Entire Capacity of Its Cigarette Factory in Greece to Smoke-Free Products
NY-GSMA21.3.2018 13:02 | pressemeddelelse
GSMA Advances a Comprehensive Agenda on Digital Inclusion for Women Ahead of G20 Summit
FUNDINFO21.3.2018 10:43 | pressemeddelelse
fundinfo Launches New Fund News Service in Cooperation with UBS
NJ-MSD-ANIMAL-HEALTH21.3.2018 07:02 | pressemeddelelse
MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO® Plus (fluralaner plus moxidectin) Spot-on Solution for Cats
GEMALTO21.3.2018 07:02 | pressemeddelelse
Gemalto Unveils Two New Enhanced Security Features for ID Documents
LIAF20.3.2018 19:29 | pressemeddelelse
LIAF: Experts at the European Parlament - E-Cigarettes Are a Potential Game Changer for European Health
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum